ClinicalTrials.gg
CompletedNCT01336023DUAL™ IUpdated Feb 19, 2018Results posted

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

A Phase 3 interventional study of insulin degludec/liraglutide and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 302 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-19.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,663
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
2nd of 70
1,663 · median 384
Started
2011
with 7 others
Phase 3
49 of 70
2 open now
Registered
20th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 20th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 1,663 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with type 2 diabetes
  • 7.0-10.0 % (both inclusive) with the aim of a median HbA1c of 8.3%. Accordingly, when approximately 50% of the randomised subjects have a HbA1c above 8.3%, the remaining subjects randomised must have a HbA1c of below or equal to 8.3%, or when approximately 50% of the randomised subjects have a HbA1c of below or equal to 8.3%, the remaining subjects randomised must have a HbA1c above 8.3%
  • Male or female, age 18 years or above (Taiwan: 20 years or above for a site 653 in Taiwan: Taichung Veterans General Hospital)
  • Subjects on stable dose of 1-2 OADs (metformin [at least 1500 mg or max tolerated dose] or metformin [at least 1500 mg or max tolerated dose] + pioglitazone [at least 30 mg]) for at least 90 days prior to screening
  • (BMI) maximum 40 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with insulin (except for short-term treatment due to intercurrent illness at the discretion of the Investigator)
  • Treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (eg exenatide, liraglutide), sulphonylurea or dipeptidyl peptidase 4 (DPP-4) inhibitors within 90 days prior to trial
  • Impaired liver function, defined as alanine aminotransferese (ALAT) at least 2.5 times Upper Normal Range (UNR) (one retest analysed at the central laboratory within a week from first sample taken is permitted with the result of the last sample being the conclusive)
  • Impaired renal function defined as serum-creatinine at least 133 mcmol/l (at least 1.5 mg/dl) for males and at least 125 mcmol/l (at least 1.4) for females, or as allowed according to local for metformin (one retest analysed at the central laboratory within a week from first sample taken is permitted with the result of the last sample being the conclusive)
  • Screening calcitonin at least 50 ng/L
  • Subjects with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Cardiac disorder defined as: congestive heart failure ( class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 12 months and planned coronary, carotid or peripheral artery revascularisation procedures
  • Severe uncontrolled treated or untreated hypertension (systolic blood pressure at least 180 mm Hg or diastolic blood pressure at least 100 mm Hg)
  • Acute treatment required proliferative retinopathy or maculopathy (macular oedema)
  • History of chronic pancreatitis or idiopathic acute pancreatitis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,663 participants (actual)

Study arms

  • Experimental
    IDeg

    Drug: insulin degludec

  • Experimental
    IDegLira

    Drug: insulin degludec/liraglutide

  • Experimental
    Lira

    Drug: liraglutide

Interventions

  • Druginsulin degludec/liraglutide

    Drug pages: Insulin degludecStudies of Insulin degludecInsulin degludec pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.

  • Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.

  • Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.

07

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.

    Values of mean change in HbA1c.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Mean Change From Baseline in Body Weight at Week 26

    Values of mean change in body weight.

    Time frame: Week 0, Week 26

  2. Number of Hypoglycaemic Episodes

    Reported hypoglycemaic episodes are number of hypoglycemic events per 100 patient years of exposure.

    Time frame: Weeks 0-26

  3. Change From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal Test

    Values of mean change in normalised iAUC0-4h values based on LOCF data derived from the glucose concentration profiles during a meal test. The meal test was performed at selected sites at baseline and after 26 weeks of treatment in the main trial period. The incremental AUC was calculated using the trapezoidal method and the resulting area was divided length of the observation period to yield the (normalised) prandial increment in mmol/L using the available valid glucose observations and the associated actual elapsed time point.

    Time frame: Week 0, Week 26

  4. Mean Actual Daily Insulin Dose

    Mean of the actual doses recorded at visit 28 (Week 26).

    Time frame: Week 26

08

Results

Posted Jun 2, 2017

Participant flow

Countries: 19; Sites: 271; Number of sites as in parenthesis. Australia (7), Canada (14 ), Finland (5 ), Germany (12 ), Hungary (6), India (23), Ireland (2), Italy (6), Malaysia (5), Mexico (2 ), Russian Federation (11), Singapore (3), Slovakia (5), South Africa (13), Spain (8), Taiwan (3), Thailand (4), United Kingdom (16) and United States (126).

Week 0 to Week 26
Participant flow — Week 0 to Week 26
MilestoneIDegIDegLiraLiraglutide
Started414834415
Exposed413826413
Completed366736342
Not completed489873
Withdrew: Adverse event81024
Withdrew: Lack of efficacy010
Withdrew: Protocol violation120
Withdrew: Withdrawal criteria346940
Withdrew: Unclassified5169
Week 27 to 52
Participant flow — Week 27 to 52
MilestoneIDegIDegLiraLiraglutide
Started333665313
Completed305621285
Not completed284428
Withdrew: Adverse event152
Withdrew: Protocol violation021
Withdrew: Withdrawal criteria141916
Withdrew: Unclassified13189

Outcome measures

PrimaryMean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.

Values of mean change in HbA1c.

Time frame:
Week 0, week 26
Reported as:
Mean · Percentage of glycosylated haemoglobin
Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.
Percentage of glycosylated haemoglobinIDegIDegLiraLiraglutide
Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.-1.44 ± 1.03-1.91 ± 1.07-1.28 ± 1.13
Statistical analysis
  • IDeg vs IDegLira · ANCOVA · Treatment contrast: -0.47 · 95% CI -0.58 to -0.36IDegLira minus IDeg
  • IDegLira vs Liraglutide · ANCOVA · Treatment contrast: -0.64 · 95% CI -0.75 to -0.53IDegLira minus Liraglutide
SecondaryMean Change From Baseline in Body Weight at Week 26

Values of mean change in body weight.

Time frame:
Week 0, Week 26
Reported as:
Mean · kg
Mean Change From Baseline in Body Weight at Week 26
kgIDegIDegLiraLiraglutide
Mean Change From Baseline in Body Weight at Week 261.6 ± 4.0-0.5 ± 3.5-3.0 ± 3.5
SecondaryNumber of Hypoglycaemic Episodes

Reported hypoglycemaic episodes are number of hypoglycemic events per 100 patient years of exposure.

Time frame:
Weeks 0-26
Reported as:
Number · Events per 100 patient years of exposure
Number of Hypoglycaemic Episodes
Events per 100 patient years of exposureIDegIDegLiraLiraglutide
Number of Hypoglycaemic Episodes256.7180.222.0
SecondaryChange From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal Test

Values of mean change in normalised iAUC0-4h values based on LOCF data derived from the glucose concentration profiles during a meal test. The meal test was performed at selected sites at baseline and after 26 weeks of treatment in the main trial period. The incremental AUC was calculated using the trapezoidal method and the resulting area was divided length of the observation period to yield the (normalised) prandial increment in mmol/L using the available valid glucose observations and the associated actual elapsed time point.

Time frame:
Week 0, Week 26
Reported as:
Mean · mmol/L
Change From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal Test
mmol/LIDegIDegLiraLiraglutide
Change From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal Test-0.17 ± 1.98-0.87 ± 1.65-0.78 ± 1.62
SecondaryMean Actual Daily Insulin Dose

Mean of the actual doses recorded at visit 28 (Week 26).

Time frame:
Week 26
Reported as:
Mean · units
Mean Actual Daily Insulin Dose
unitsIDegIDegLira
Mean Actual Daily Insulin Dose53 ± 2838 ± 13

Adverse events

Collected over Adverse events (AEs) were collected from first day of exposure to randomised treatment of 52 weeks (26 week main period + 26 week extension period) + 7 days follow-up after the last day on randomised treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg—22/412 (5.3%)160/412 (38.8%)
IDegLira—38/825 (4.6%)386/825 (46.8%)
Liraglutide—24/412 (5.8%)241/412 (58.5%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventIDegIDegLiraLiraglutide
OsteoarthritisMusculoskeletal and connective tissue disorders0/4121/8253/412
Angina pectorisCardiac disorders0/4122/8252/412
Angina unstableCardiac disorders2/4120/8250/412
Umbilical herniaGastrointestinal disorders0/4120/8252/412
CholelithiasisHepatobiliary disorders2/4120/8251/412
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/4120/8250/412
Acute coronary syndromeCardiac disorders1/4120/8250/412
Acute myocardial infarctionCardiac disorders1/4122/8251/412
Atrial fibrillationCardiac disorders0/4121/8251/412
GoitreEndocrine disorders0/4120/8251/412
Most frequent other events
Showing 10 of 13
Most frequent other events
EventIDegIDegLiraLiraglutide
NauseaGastrointestinal disorders16/41285/82592/412
DiarrhoeaGastrointestinal disorders28/41284/82567/412
HeadacheNervous system disorders45/412106/82560/412
NasopharyngitisInfections and infestations52/412115/82555/412
VomitingGastrointestinal disorders10/41241/82537/412
Lipase increasedInvestigations18/41248/82535/412
Upper respiratory tract infectionInfections and infestations34/41264/82533/412
Decreased appetiteMetabolism and nutrition disorders2/41222/82530/412
Back painMusculoskeletal and connective tissue disorders20/41245/82523/412
DyspepsiaGastrointestinal disorders5/41228/82522/412

Baseline characteristics

The full analysis set (FAS) included all randomised subjects and missing data was imputed using last observation carried forward (LOCF). Three subjects did not have their case book signed off due to discontinuation of an investigator's participation in the trial, hence 1 subject in each arm was excluded from the FAS.

Age, Continuous
Age, Continuous(years)IDegIDegLiraLiraglutideTotal
Mean54.9 ± 9.755.1 ± 9.955.0 ± 10.255.0 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)IDegIDegLiraLiraglutideTotal
Female213398206817
Male200435208843
Body Weight
Body Weight(kg)IDegIDegLiraLiraglutideTotal
Mean87.4 ± 19.287.2 ± 19.087.4 ± 18.087.3 ± 18.8
Normalised Incremental Area under curve (AUC)
Normalised Incremental Area under curve (AUC)(mmol/L)IDegIDegLiraLiraglutideTotal
Mean4.12 ± 1.804.11 ± 2.054.12 ± 1.824.11 ± 1.93
Glycosylated haemoglobin (HbA1c)
Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin)IDegIDegLiraLiraglutideTotal
Mean8.3 ± 1.08.3 ± 0.98.3 ± 0.98.3 ± 0.9
09

Study locations

302 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35216, United States
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Bermuda Dunes, California 92203, United States
  • Novo Nordisk Investigational Site
    Concord, California 94520, United States
  • Novo Nordisk Investigational Site
    Encino, California 91436, United States
  • Novo Nordisk Investigational Site
    Fair Oaks, California 95628, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93702, United States
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90807, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    Monterey, California 93940, United States
  • Novo Nordisk Investigational Site
    Orange, California 92868, United States
  • Novo Nordisk Investigational Site
    Poway, California 92064, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92117, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92161-0002, United States
  • Novo Nordisk Investigational Site
    San Mateo, California 94401, United States
  • Novo Nordisk Investigational Site
    Santa Barbara, California 93105, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780, United States
  • Novo Nordisk Investigational Site
    Valencia, California 91355, United States
  • Novo Nordisk Investigational Site
    Walnut Creek, California 94598, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80910, United States
  • Novo Nordisk Investigational Site
    Denver, Colorado 80209, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Waterbury, Connecticut 06708, United States
  • Novo Nordisk Investigational Site
    Newark, Delaware 19713, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33765, United States
  • Novo Nordisk Investigational Site
    Delray Beach, Florida 33484, United States
  • Novo Nordisk Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33012, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32258, United States
  • Novo Nordisk Investigational Site
    Kissimmee, Florida 34741, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32934, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33135, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32804, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33027, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33603, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Columbus, Georgia 31909, United States
  • Novo Nordisk Investigational Site
    Conyers, Georgia 30094-5965, United States
  • Novo Nordisk Investigational Site
    Decatur, Georgia 30035, United States
  • Novo Nordisk Investigational Site
    Lawrenceville, Georgia 30046, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Woodstock, Georgia 30189-4255, United States
  • Novo Nordisk Investigational Site
    Meridian, Idaho 83646, United States
  • Novo Nordisk Investigational Site
    Nampa, Idaho 83686-6011, United States
  • Novo Nordisk Investigational Site
    Avon, Illinois 46123, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Gurnee, Illinois 60031, United States
  • Novo Nordisk Investigational Site
    O'Fallon, Illinois 62246, United States
  • Novo Nordisk Investigational Site
    Fishers, Indiana 46038-1862, United States
  • Novo Nordisk Investigational Site
    Franklin, Indiana 46131, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46254, United States
  • Novo Nordisk Investigational Site
    Michigan City, Indiana 46360, United States
  • Novo Nordisk Investigational Site
    Muncie, Indiana 47304, United States
  • Novo Nordisk Investigational Site
    Crestview Hills, Kentucky 41017-3464, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70006-2930, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70006, United States
  • Novo Nordisk Investigational Site
    Hyattsville, Maryland 20782, United States
  • Novo Nordisk Investigational Site
    North East, Maryland 21901, United States
  • Novo Nordisk Investigational Site
    Rockville, Maryland 20852, United States
  • Novo Nordisk Investigational Site
    Buckley, Michigan 49620, United States
  • Novo Nordisk Investigational Site
    Southfield, Michigan 48034-7661, United States
  • Novo Nordisk Investigational Site
    Southfield, Michigan 48075, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48098, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64111, United States
  • Novo Nordisk Investigational Site
    Saint Charles, Missouri 63303, United States
  • Novo Nordisk Investigational Site
    Henderson, Nevada 89052-2649, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89102, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Flemington, New Jersey 08822-5763, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08753-2975, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12206, United States
  • Novo Nordisk Investigational Site
    Bronx, New York 10461, United States
  • Novo Nordisk Investigational Site
    Northport, New York 11768, United States
  • Novo Nordisk Investigational Site
    Syracuse, New York 13210, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Asheboro, North Carolina 27203, United States
  • Novo Nordisk Investigational Site
    Asheville, North Carolina 28801, United States
  • Novo Nordisk Investigational Site
    Burlington, North Carolina 27215, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28277, United States
  • Novo Nordisk Investigational Site
    Greensboro, North Carolina 27408, United States
  • Novo Nordisk Investigational Site
    Greenville, North Carolina 27834, United States
  • Novo Nordisk Investigational Site
    Morehead City, North Carolina 28557, United States
  • Novo Nordisk Investigational Site
    Shelby, North Carolina 28152, United States
  • Novo Nordisk Investigational Site
    Statesville, North Carolina 28625, United States
  • Novo Nordisk Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Novo Nordisk Investigational Site
    Canton, Ohio 44718, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45224, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45242-4494, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45242, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44113, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43213, United States

Showing the first 100 of 302 sites across 20 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Khunti K, Mohan V, Jain SM, Boesgaard TW, Begtrup K, Sethi B. Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program. Diabetes Ther. 2017 Jun;8(3):673-682. doi: 10.1007/s13300-017-0252-9. Epub 2017 Mar 22. PubMed 28332144 ↗
  • Holst JJ, Buse JB, Rodbard HW, Linjawi S, Woo VC, Boesgaard TW, Kvist K, Gough SC. IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. J Diabetes Sci Technol. 2015 Oct 6;10(2):389-97. doi: 10.1177/1932296815610124. PubMed 26443290 ↗
  • Vilsboll T, Vora J, Jarlov H, Kvist K, Blonde L. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clin Drug Investig. 2016 Apr;36(4):293-303. doi: 10.1007/s40261-016-0376-0. PubMed 26894800 ↗
  • Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1. PubMed 25190523 ↗
  • Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015 Oct;17(10):965-73. doi: 10.1111/dom.12498. Epub 2015 Jul 1. PubMed 25980900 ↗
  • Kapitza C, Bode B, Ingwersen SH, Jacobsen LV, Poulsen P. Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol. 2015 Dec;55(12):1369-77. doi: 10.1002/jcph.549. Epub 2015 Jul 14. PubMed 25998481 ↗
  • King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsboll T. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. Diabetes Technol Ther. 2017 Apr;19(4):255-264. doi: 10.1089/dia.2016.0405. Epub 2017 Mar 10. PubMed 28282219 ↗
  • Norwood P, Chen R, Jaeckel E, Lingvay I, Jarlov H, Lehmann L, Heller S. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Diabetes Obes Metab. 2017 Nov;19(11):1562-1569. doi: 10.1111/dom.12972. Epub 2017 Jul 10. PubMed 28417535 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in May 2012, 12 months.

Results were first posted in Jun 2017, 5 years after primary completion. A results delay was requested in Dec 2012.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2011
First posted
Apr 15, 2011
StartActual
May 23, 2011
Primary completionActual
May 24, 2012
CompletionActual
Nov 22, 2012
Results delay requested
Dec 19, 2012
Results first posted
Jun 2, 2017
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01336023
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 15, 2011
Start date
May 23, 2011
Primary completion
May 24, 2012
Completion
Nov 22, 2012
Results posted
Jun 2, 2017
Last update
Feb 19, 2018

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion